1.12422

N-Acetyl-L-cysteine

for biochemistry

• Synonym(s): N-Acetyl-L-cysteine, 2-Acetamido-3-mercaptopropionic acid
• Empirical Formula (Hill Notation): C₅H₉NO₃S
• CAS Number: 616-91-1
• Molecular Weight: 163.19
• MDL number: MFCD00004880
• UNSPSC Code: 12352209
• EC Index Number: 210-498-3

Properties

• vapor pressure: <1 hPa ( 20 °C)
• Quality Level: 100
• form: solid
• potency: 5050 mg/kg LD₅₀, oral (Rat)
• pH: 1.5-2.5 (20 °C, 100 g/L in H₂O)
• mp: 110.4 °C
• solubility: 179.5 g/L
• density: 1.48 g/cm³ at 20 °C
• bulk density: 730 kg/m³
• storage temp.: 2-30°C
• InChI: 1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)
• InChI key: PWKSKIMOESPYIA-UHFFFAOYSA-N

Description

Application

• Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis: This study presents a novel N-Acetyl-L-cysteine application in aerosol form designed to treat Pseudomonas aeruginosa biofilm infections in cystic fibrosis patients, highlighting its potential to improve pulmonary function and reduce bacterial colonization (Alhajj et al., 2024).


• Emetine induces oxidative stress, cell differentiation and NF-κB inhibition, suppressing AML stem/progenitor cells: Research indicates that N-Acetyl-L-cysteine, as part of a combinatory therapy, enhances the oxidative stress response in acute myeloid leukemia, providing a therapeutic strategy for targeting leukemia stem cells (Silva et al., 2024).


• N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses: This meta-analysis reveals N-Acetyl-L-cysteine′s effectiveness in reducing exacerbations and improving antioxidant defense in COPD and chronic bronchitis, suggesting a significant therapeutic benefit in respiratory disease management (Papi et al., 2024).


• Tannic acid- and N-acetylcysteine-chitosan-modified magnetic nanoparticles reduce hepatic oxidative stress in prediabetic rats: N-Acetyl-L-cysteine, used in modifying magnetic nanoparticles, shows promising results in reducing oxidative stress and liver damage in a prediabetic rat model, underscoring its potential in preventive therapies (Świętek et al., 2024).


• Phenylarsine oxide induced corneal injury involves oxidative stress mediated unfolded protein response and ferroptotic cell death: Amelioration by NAC: This research outlines N-Acetyl-L-cysteine′s role in mitigating oxidative stress and ferroptosis in corneal cells, providing insights into its protective effects against chemical-induced ocular damage (Kandhari et al., 2023).

Analysis Note

Assay (iodometric): ≥ 99.0 %
Identity (IR-spectrum): passes test
Appearance: white to almost white, crystalline powder or colorless crystals
Appearance of solution (1 mol/l, water): clear and colorless
Spec. rotation (α 20/D, 50 g/l, buffer pH 7.0): +21.0 to +27.0
Heavy metals (as Pb): ≤ 0.001 %
NH₄ (Ammonium): ≤ 0.01 %
L-cysteine (HPLC): ≤ 0.02 %
Other ninhydrine positive substances: ≤ 0.1 %

Safety Information

• Pictograms: GHS07
• Signal Word: Warning
• Hazard Statements: H319
• Precautionary Statements: P264 - P280 - P305 + P351 + P338 - P337 + P313
• Hazard Classifications: Eye Irrit. 2
• Storage Class Code: 13 - Non Combustible Solids
• WGK: WGK 2
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable